 |
|
Daily Digest
November 16, 2026
Volume 8, Issue 2
|
|
What’s Inside Today
The Food and Drug Administration on November 16 proposed a rule that would reverse the exclusion of N-acetyl-L-cysteine (NAC) from the dietary supplement definition, the first time the agency has moved by rulemaking to lift an exclusion under DSHEA’s drug preclusion clause. The proposal is scheduled for Federal Register publication on November 17 and opens a public comment period. The Council for Responsible Nutrition said it supports the rule but that the proposal does not give other ingredients a predictable path, and it renewed its call for Congress to pass the Dietary Supplement Innovation Act. Separately, a National Advertising Review Board panel said it will refer Mammoth Brands, the maker of Harry’s razors, to the Federal Trade Commission after the company did not confirm it would comply with the panel’s recommendations.
|
|
|
|
Today’s Lead
|
|
Nutritional Outlook | November 16, 2026
FDA announced a proposed rule on November 16 that would reverse its position that NAC is excluded from the dietary supplement definition, according to an agency constituent update reported by Nutritional Outlook. The agency has said NAC fell outside the definition because it was approved as a drug in 1963, before any supplement marketing the agency could identify, and it has relied on an enforcement discretion policy for NAC products since 2022. The proposal would create a new regulation, 21 CFR 190.1, to list dietary ingredients that are not excluded from the definition, with NAC as the first entry. Nutritional Outlook reports that comments are due 60 days after publication, that a pre-publication copy is scheduled to appear in the Federal Register on November 17, and that FDA proposed that a final rule take effect immediately upon publication.
|
|
|
|
|
Advertising Self-Regulation Watch
|
|
BBB National Programs, National Advertising Review Board | November 16, 2026
In a challenge brought by The Gillette Company, a panel of the National Advertising Review Board, the appellate body of BBB National Programs, found that survey data supported Harry’s claims about how many Gillette users said they would shave with Harry’s Plus razors. The panel recommended that Mammoth Brands discontinue certain claims it found disparaged Gillette, along with a Gillette Labs commercial. Because Mammoth Brands did not confirm it would comply, NARB said on November 16 that it will refer the company to regulatory authorities, including the Federal Trade Commission.
|
|
|
|
|
NMN and the Drug Preclusion Clause
|
|
Chain Drug Review | November 16, 2026
The Council for Responsible Nutrition said it supports FDA’s proposed NAC rule and will file comments. CRN, whose citizen petition on NAC was denied by FDA in September 2025, said the proposal does not provide a predictable process for adding other ingredients to the new list and leaves broader questions about the drug preclusion framework unresolved. The association said the rule shows the need for legislation such as the Dietary Supplement Innovation Act (H.R. 10336), which was introduced in the House on September 10 and referred to the Energy and Commerce Committee.
|
|
|
Your Voice Matters
FDA’s proposed NAC rule opens a 60 day public comment period upon Federal Register publication, scheduled for November 17, 2026. The comment record will inform how the agency applies DSHEA’s drug preclusion clause in a final rule. Visit DSHEA.org to learn how to submit a comment.
|
|
DSHEA Preservation Alliance
Powered by PICXM
|
|